Evidence map›Paper›PMID 42850288›Full record

ArticleMolecular systems biology2026

Validation and analysis of 12,000 AI-driven CAR-T designs in the Bits to Binders competition.

Clayton W Kosonocky, Alex M Abel, Aaron L Feller, Amanda E Cifuentes Rieffer, Phillip R Woolley, Jakub Lála, Daryl R Barth, Tynan Gardner, Bits to Binders Competitors, Stephen C Ekker and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Clayton W Kosonocky *Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-6420-8615
Alex M Abel *LifEngine Animal Health (LEAH) Laboratories Incorporated, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0003-4022-2495
Aaron L FellerDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Amanda E Cifuentes RiefferLifEngine Animal Health (LEAH) Laboratories Incorporated, Minneapolis, MN, USA.
Phillip R WoolleyDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Jakub LálaDepartment of Materials, Imperial College London, London, United Kingdom.
Daryl R BarthDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0003-3690-3909
Tynan GardnerDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Bits to Binders Competitors
Stephen C EkkerDepartment of Pediatrics, Dell Medical School, University of Texas at Austin, Austin, TX, USA.
Andrew D EllingtonDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Wesley A WiersonLifEngine Animal Health (LEAH) Laboratories Incorporated, Minneapolis, MN, USA.
Edward M MarcotteDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA. marcotte@utexas.edu.ORCID http://orcid.org/0000-0001-8808-180X

Funding

Proteomics and model organism humanization to decode human geneticsR35GM122480 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI EDWARD M MARCOTTE · 2017 to 2026
$5.4M
BioMADE T-OC-A-04-0087DOW | Defense Threat Reduction Agency (DTRA) HDTRA1201001Foundation for the National Institutes of Health (FNIH) R35GM122480Welch Foundation (The Welch Foundation) F-1515Welch Foundation (The Welch Foundation) F-1654
6 · The paper itself

Abstract

Artificial intelligence (AI) methods for proteins have advanced rapidly, improving structure prediction and design, particularly for de novo binders. However, most evaluations emphasize binding affinity rather than higher-order biological function. We present Bits to Binders, a global competition evaluating de novo binder design in the context of chimeric antigen receptor (CAR) T cells. Teams from 42 countries submitted 12,000 designs of 80-amino acid de novo minibinders targeting human CD20 as CAR binding domains. Designs were screened by pooled CAR-T proliferation, identifying 707 designs exhibiting significant CD20-specific enrichment, with team hit rates from 0.6% to 38.4%. Top-performing candidates were validated as individual constructs, measuring CD20-specific proliferation, expansion, cytokine production, and targeted cell lysis. We identified common design methodologies and factors correlated with DNA synthesis, expression, and target-specific T cell activation which nearly double the success rates when applied as a retrospective filter. We release this dataset as an open resource, with practical recommendations to support more effective AI-driven binder design.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.